Leading BioSolutions Platform

Financial Results: H1 FY2020 Crore FY20 FY 19 Change Particulars H-1 PPA / H-1 H-1 % % % Reported Integration (Note 1) (Note 2) Total Revenue from operation 15,723 15,723 100% 8,391 100% 87% Variable Cost 9,468 414 9,054 58% 4,752 57% Gross Margin 6,255 (414) 6,669 42% 3,639 43% 83% Fixed Overheads 3,470 0 3,470 22% 1,953 23% EBITDA 2,785 (414) 3,199 20% 1,686 20% 90% Other Income/ (Loss) (36) (36) 53 Amortization / Depreciation 1,185 303 882 356 Finance Cost 779 779 356 PBT 785 (717) 1,502 10% 1,027 12% 46% Tax 78 (215) 293 167 PAT 707 (502) 1,209 8% 859 10% 41% Income/(Loss) from Associate Co. and JV (12) (12) (10) Minority Interest 52 52 8 Profit After Tax, Associate Income & 643 (502) 1,145 7% 841 10% 36% Minority Interest Exceptional Cost Net Profit 376 267 376 61 (502) 769 5% 780 9% -1% Note : 1) Purchase Price Allocation effect and Integration cost are removed from H1 FY2020 UPL 2) Previous years numbers (without Arysta) have been regrouped for comparison purpose. 3) Exceptional cost includes full provision of Rs. 217 crore towards Jury verdict on Agrofresh litigation, Rs. 159 crore are towards redundancy and other integration related costs 49

View entire presentation